Citigroup’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.45M | Hold |
100,000
| – | – | ﹤0.01% | 2875 |
|
|
2025
Q4 | $1.42M | Buy |
+100,000
| New | +$982K | ﹤0.01% | 2894 |
|
|
2025
Q1 | – | Sell |
-124,900
| Closed | -$1.18M | – | 5707 |
|
|
2024
Q4 | $1.18M | Sell |
124,900
-99,900
| -44% | -$1.04M | ﹤0.01% | 3235 |
|
|
2024
Q3 | $2.4M | Buy |
224,800
+194,900
| +652% | +$2.12M | ﹤0.01% | 2502 |
|
|
2024
Q2 | $297K | Sell |
29,900
-39,800
| -57% | -$409K | ﹤0.01% | 3689 |
|
|
2024
Q1 | $821K | Buy |
69,700
+10,900
| +19% | +$139K | ﹤0.01% | 3185 |
|
|
2023
Q4 | $834K | Sell |
58,800
-32,700
| -36% | -$371K | ﹤0.01% | 2983 |
|
|
2023
Q3 | $1.11M | Sell |
91,500
-61,200
| -40% | -$789K | ﹤0.01% | 2417 |
|
|
2023
Q2 | $1.92M | Buy |
152,700
+20,000
| +15% | +$237K | ﹤0.01% | 2256 |
|
|
2023
Q1 | $1.47M | Buy |
132,700
+32,700
| +33% | +$403K | ﹤0.01% | 2235 |
|
|
2022
Q4 | $1.22M | Buy |
100,000
+60,000
| +150% | +$675K | ﹤0.01% | 2438 |
|
|
2022
Q3 | $418K | Hold |
40,000
| – | – | ﹤0.01% | 3369 |
|
|
2022
Q2 | $430K | Buy |
+40,000
| New | +$329K | ﹤0.01% | 3347 |
|
|
2021
Q1 | – | Sell |
-23,300
| Closed | -$538K | – | 6641 |
|
|
2020
Q4 | $538K | Buy |
23,300
+17,100
| +276% | +$350K | ﹤0.01% | 4144 |
|
|
2020
Q3 | $88K | Sell |
6,200
-7,800
| -56% | -$114K | ﹤0.01% | 5210 |
|
|
2020
Q2 | $211K | Buy |
14,000
+6,400
| +84% | +$78K | ﹤0.01% | 4972 |
|
|
2020
Q1 | $70K | Sell |
7,600
-4,500
| -37% | -$42.8K | ﹤0.01% | 5662 |
|
|
2019
Q4 | $118K | Buy |
12,100
+700
| +6% | +$6.41K | ﹤0.01% | 5613 |
|
|
2019
Q3 | $91K | Sell |
11,400
-400
| -3% | -$4.34K | ﹤0.01% | 5742 |
|
|
2019
Q2 | $147K | Buy |
11,800
+11,600
| +5,800% | +$147K | ﹤0.01% | 5528 |
|
|
2019
Q1 | $3K | Sell |
200
-20,000
| -99% | -$244K | ﹤0.01% | 7487 |
|
|
2018
Q4 | $194K | Sell |
20,200
-16,000
| -44% | -$176K | ﹤0.01% | 5049 |
|
|
2018
Q3 | $438K | Buy |
36,200
+26,900
| +289% | +$376K | ﹤0.01% | 4442 |
|
|
2018
Q2 | $145K | Sell |
9,300
-26,300
| -74% | -$398K | ﹤0.01% | 5369 |
|
|
2018
Q1 | $535K | Sell |
35,600
-4,300
| -11% | -$65.4K | ﹤0.01% | 3916 |
|
|
2017
Q4 | $574K | Sell |
39,900
-34,700
| -47% | -$477K | ﹤0.01% | 3962 |
|
|
2017
Q3 | $1.13M | Buy |
74,600
+42,300
| +131% | +$560K | ﹤0.01% | 3246 |
|
|
2017
Q2 | $325K | Buy |
32,300
+12,100
| +60% | +$97.4K | ﹤0.01% | 4376 |
|
|
2017
Q1 | $144K | Sell |
20,200
-13,200
| -40% | -$83.5K | ﹤0.01% | 4928 |
|
|
2016
Q4 | $166K | Buy |
33,400
+15,500
| +87% | +$107K | ﹤0.01% | 5438 |
|
|
2016
Q3 | $132K | Buy |
17,900
+7,900
| +79% | +$53.4K | ﹤0.01% | 5009 |
|
|
2016
Q2 | $55K | Buy |
10,000
+7,900
| +376% | +$55.2K | ﹤0.01% | 5509 |
|
|
2016
Q1 | $18K | Sell |
2,100
-6,900
| -77% | -$48.9K | ﹤0.01% | 6592 |
|
|
2015
Q4 | $87K | Buy |
9,000
+3,400
| +61% | +$30.6K | ﹤0.01% | 5485 |
|
|
2015
Q3 | $78K | Buy |
5,600
+4,300
| +331% | +$67.4K | ﹤0.01% | 5129 |
|
|
2015
Q2 | $18K | Buy |
+1,300
| New | +$15.6K | ﹤0.01% | 6165 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Citigroup's FOLD Position: Q1 2026 in Review
Citigroup increased its Amicus Therapeutics (FOLD) stake by 156% in Q1 2026, buying an estimated $37M and bringing the position to 4,226,882 shares worth $61.1M. The position accounts for 0.03% of the portfolio, ranked #566.
Citigroup first reported a position in FOLD in Q2 2013 and has held it in 51 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Citigroup held 4,226,882 shares of Amicus Therapeutics worth $61.1M as of Q1 2026.
- Citigroup bought 2,578,335 Amicus Therapeutics shares in Q1 2026, an estimated $37M.
- Amicus Therapeutics made up 0.03% of Citigroup's portfolio in Q1 2026, its #566 holding.
- Citigroup first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 51 quarters since.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.